IDSA GUIDELINES Bundle (free trial)

Chronic Kidney Disease in HIV-Infected Patients

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/418521

Contents of this Issue

Navigation

Page 10 of 15

Table 4. Dosing of Antiretroviral Drugs for HIV-Infected Adults With CKD or ESRD (continued) Antiretroviral Drug and Dosing Category Dosage Comments Nucleoside reverse transcriptase inhibitors (NRTIs) (continued) Stavudine Body weight ≥60 kg CrCl >50 mL/min 40 mg PO bid (WHO recommends 30 mg PO bid) CrCl 26-50 mL/min 20 mg PO bid CrCl ≤25 mL/min 20 mg PO daily Receiving HD 20 mg PO daily a Receiving PD Unknown, use with caution (dose reduction needed) Body weight <60 kg CrCl >50 mL/min 30 mg PO bid CrCl 26-50 mL/min 15 mg PO bid CrCl ≤25 mL/min 15 mg PO daily Receiving HD 15 mg PO daily a Receiving PD Unknown, use with caution (dose reduction needed) Didanosine delayed-release capsules Body weight ≥60 kg CrCl ≥60 mL/min 400 mg PO daily CrCl 30-59 mL/min 200 mg PO daily CrCl 10-29 mL/min 125 mg PO daily CrCl <10 mL/min 125 mg PO daily Receiving HD 125 mg PO daily a Receiving PD 125 mg PO daily Body weight <60 kg CrCl ≥60 mL/min 250 mg PO daily CrCl 30-59 mL/min 125 mg PO daily CrCl 10-29 mL/min 125 mg PO daily CrCl <10 mL/min, HD, or PD Do not use didanosine delayed- release capsules; use 75 mg (pediatric powder for suspension) daily 9

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Chronic Kidney Disease in HIV-Infected Patients